DelveInsight’s “Dry Age-Related Macular Degeneration Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Dry Age-Related Macular Degeneration market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Dry Age-Related Macular Degeneration drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Dry Age-Related Macular Degeneration treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Dry Age-Related Macular Degeneration: An Overview
According to the American Macular Degeneration Foundation, dry age-related macular degeneration (Dry-AMD) is a type of macular degeneration in which the deterioration of the retina is associated with the formation of small yellow deposits, known as drusen, under the macula. This phenomenon leads to a thinning and drying out of the macula, causing the macula to lose its function. The amount of central vision loss is directly related to the location and amount of retinal thinning caused by the drusen.
Out of two types of AMD (wet and dry), Dry-AMD is quite common. About 80% (8 out of 10) of people who have AMD have the dry form. According to Prevent Blindness, dry AMD is caused by the appearance of small yellow deposits called drusen, which form under the retina. These are accumulated waste products of the retina, which can grow in size. This can cause the retinal cells in the macula that process light to die, causing vision to become blurred. This form of the disease usually worsens slowly.
Dry Age-Related Macular Degeneration Market Key Facts
-
The total diagnosed cases of dry AMD in the US were approximately 11 million in 2022.
-
Secondary findings suggest that patients with early or intermediate AMD constitute 85–90% of all patients with AMD, and approximately 10–15% of all AMD patients eventually develop the wet form. GA corresponds to half of the exudative form.
-
The total diagnosed cases of dry AMD by stages in the US were ~10 million and 1 million cases for early and intermediate dry AMD and advanced (geographic atrophy associated with dry AMD) in 2022.
-
In the EU4 and the UK, the total diagnosed cases of dry AMD were highest in Germany, whereas Spain accounted for the least number of cases in 2022.
-
As per a study by Owen et al.(2012), for the UK, it was found that the overall prevalence of late AMD was 2.4% equivalent to 513,000 cases. Prevalence was 4.8% aged ≥65 years, 12.2% aged ≥80 years.
-
Key players like Apellis Pharmaceuticals (Pegcetacoplan), Iveric bio (Zimura), Genentech/ Roche (RO7171009; RG6147), Ionis Pharmaceuticals/ Roche (IONIS-FB-LRx), Allegro Ophthalmics (Luminate), NGM Biopharmaceuticals (NGM621), Stealth BioTherapeutics (Elamipretide), Regenerative Patch Technologies (CPCB-RPE1), CellCure Neurosciences/ Lineage Cell Therapeutics/ Roche (OpRegen), Gyroscope Therapeutics/ Novartis (GT005), Regenerative Patch Technologies (CPCB-RPE1), Luxa Biotechnology (RPESC-RPE-4W) and others. and others are involved in developing treatments for dry AMD.
Dry Age-Related Macular Degeneration Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Dry Age-Related Macular Degeneration pipeline therapies. It also thoroughly assesses the Dry Age-Related Macular Degeneration market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Dry Age-Related Macular Degeneration drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Dry Age-Related Macular Degeneration Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Dry Age-Related Macular Degeneration epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Dry Age-Related Macular Degeneration epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Dry Age-Related Macular Degeneration Epidemiology, Segmented as –
-
Total Prevalent cases of Age-related Macular Degeneration in the 7MM [2019-2032]
-
Type-specific (Dry-AMD, Wet-AMD) Prevalence of Age-related Macular Degeneration in the 7MM [2019-2032]
-
Stage-specific Prevalence of Dry Age-related Macular Degeneration in the 7MM [2019-2032]
-
Age-specific Prevalence of Dry Age-related Macular Degeneration in the 7MM [2019-2032]
-
Geographic Atrophy (GA) Cases by Visual Impairment in the 7MM [2019-2032]
Dry Age-Related Macular Degeneration Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Dry Age-Related Macular Degeneration market or expected to be launched during the study period. The analysis covers the Dry Age-Related Macular Degeneration market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares Dry Age-Related Macular Degeneration drugs based on their sale and market share.
The report also covers the Dry Age-Related Macular Degeneration pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Dry Age-Related Macular Degeneration companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Dry Age-Related Macular Degeneration Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-market
Dry Age-Related Macular Degeneration Therapeutics Analysis
The treatment landscape of Dry Age-related Macular Degeneration only consists of dietary vitamins and other supplements. Currently, there is no approved therapy for the treatment of Dry-AMD; the treatment is mainly focused on providing nutritional supplements to manage this disease. In the absence of any treatment and because of a poor correlation between BCVA and “geographic atrophy lesions or progression, a multimodal imaging approach is necessary to better follow up with geographic atrophy patients.
High doses of antioxidant vitamins (vitamins C, E, and beta-carotene) and zinc supplements are found to produce a beneficial effect in slowing the progression of d-AMD. Also, a high dietary folate intake seems to reduce the risk of progression to geographic atrophy, although this effect may be modified by the genetic profile related to C3 R102G.
Several major pharma and biotech companies are developing therapies for Dry Age-related Macular Degeneration. Currently, Alkeus Pharmaceuticals is leading the therapeutics market with its Dry Age-related Macular Degeneration drug candidates in the most advanced stage of clinical development.
Dry Age-Related Macular Degeneration Companies Actively Working in the Therapeutics Market Include
-
4D Molecular Therapeutics
-
Aevitas Therapeutics
-
Alexion AstraZeneca Rare Disease
-
Amarna Therapeutics
-
Apellis Pharmaceuticals
-
Aviceda Therapeutics
-
Belite Bio
-
Cognition Therapeutics
-
Galimedix Therapeutics
-
InflammX Therapeutics
-
Isarna Therapeutics
-
Katairo
-
Lineage Cell Therapeutics
-
Molecular Partners
-
NGM Biopharmaceuticals
-
Regenerative Patch Technologies
-
Stealth BioTherapeutics
And many others
Emerging and Marketed Dry Age-Related Macular Degeneration Therapies Covered in the Report Include:
-
ALK-001: Alkeus Pharmaceuticals
-
Elamipretide: Stealth BioTherapeutics
-
CPCB-RPE1: Regenerative Patch Technologies
-
AAV.sFH: Aevitas Therapeutics
And many more
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Dry Age-Related Macular Degeneration Competitive Intelligence Analysis
4. Dry Age-Related Macular Degeneration Market Overview at a Glance
5. Dry Age-Related Macular Degeneration Disease Background and Overview
6. Dry Age-Related Macular Degeneration Patient Journey
7. Dry Age-Related Macular Degeneration Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Dry Age-Related Macular Degeneration Treatment Algorithm, Current Treatment, and Medical Practices
9. Dry Age-Related Macular Degeneration Unmet Needs
10. Key Endpoints of Dry Age-Related Macular Degeneration Treatment
11. Dry Age-Related Macular Degeneration Marketed Therapies
12. Dry Age-Related Macular Degeneration Emerging Drugs and Latest Therapeutic Advances
13. Dry Age-Related Macular Degeneration Seven Major Market Analysis
14. Attribute Analysis
15. Dry Age-Related Macular Degeneration Market Outlook (In US, EU5, and Japan)
16. Dry Age-Related Macular Degeneration Companies Active in the Market
17. Dry Age-Related Macular Degeneration Access and Reimbursement Overview
18. KOL Views on the Dry Age-Related Macular Degeneration Market
19. Dry Age-Related Macular Degeneration Market Drivers
20. Dry Age-Related Macular Degeneration Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Partial Onset Seizures Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Partial Onset Seizures market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Partial Onset Seizures market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices